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SUMMARY
The EGLN (also called PHD) prolyl hydroxylase enzymes and their canonical targets, the HIFα 
subunits, represent the core of an ancient oxygen-monitoring machinery used by metazoans. In 
this review we highlight recent progress in understanding the overlapping versus specific roles of 
EGLN enzymes and HIF isoforms and discuss how feedback loops based on recently identified 
noncoding RNAs introduce additional layers of complexity to the hypoxic response. Based on 
novel interactions identified upstream and downstream of EGLNs, an integrated network 
connecting oxygen-sensing functions to metabolic and signaling pathways is gradually emerging 
with broad therapeutic implications.
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The Core of Oxygen Sensing in Metazoans
How animal cells adapt to variations in ambient oxygen concentration was a recurring 
question during the 20th century, as groups from diverse fields joined the quest for an elusive 
“sensor”. Studies of the prototypical hypoxia-responsive mRNA encoding EPO led to the 
identification over 20 years ago of a hypoxia-inducible activity called hypoxia-inducible 
factor or “HIF”. Contrary to the prevailing expectations at that time, HIF was soon detected 
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in a wide variety of hypoxic cells and tissues and not just specialized cells dedicated to 
producing EPO. Subsequent studies showed that HIF is a heterodimer consisting of alpha 
subunit, such as the first alpha subunit to be cloned, hypoxia-inducible factor alpha (HIF1α), 
and a beta subunit. The alpha subunit is a basic helix–loop–helix, PAS domain–containing, 
DNA-binding protein that is rapidly degraded in normoxic cells (Kaelin and Ratcliffe, 2008). 
As oxygen tension decreases, HIFα becomes progressively more stable and binds its partner 
HIFβ, the oxygen- insensitive protein product of the ARNT gene. The resulting complex 
undergoes nuclear translocation, binds to hypoxia-response elements (HREs) and 
transcriptionally activates hundreds of genes involved in low oxygen adaptation (Kaelin and 
Ratcliffe, 2008; Semenza, 2012).
The discovery that cells lacking the pVHL tumor suppressor protein accumulate high levels 
of hypoxia-inducible mRNAs, and do not degrade HIF, even when oxygen is plentiful 
ultimately led to the recognition that pVHL is the substrate recognition module of the 
ubiquitin ligase that targets HIFα for proteasomal degradation under normoxic conditions. 
While the discovery of HIF, and its regulation by pVHL, provided key mechanistic insights 
into the coordinated activation of the hypoxic transcriptome, it did not immediately reveal 
the oxygen sensor’s identity. A major step forward was the demonstration that two 
conserved prolyl residues within the region of HIFα that is recognized by pVHL, called the 
oxygen-dependent degradation domain, are enzymatically hydroxylated in an oxygen-
dependent manner (Ivan et al., 2001; Jaakkola et al., 2001; Masson et al., 2001; Yu et al., 
2001). Hydroxylation of either (or both) of these prolyl residues generates a high-affinity 
binding site for pVHL, leading to HIFα’s polyubiquitylation and destruction in well-
oxygenated cells. HIF prolyl hydroxylation is mediated by the EGLN (also called PHD) 2-
oxoglutarate (2OG)–dependent dioxygenases, which require oxygen, iron, and 2-
oxoglutarate to function (Bruick and McKnight, 2001; Epstein et al., 2001; Ivan et al., 
2002). Importantly, the EGLNs have relatively low oxygen affinities and hence are poised to 
sense oxygen in a physiologically relevant concentration range (Kaelin and Ratcliffe, 2008).
The EGLNs are highly susceptible to self-inactivation as a result of autooxidiation. As a 
result, antioxidants such as ascorbate are usually included when measuring EGLN activity in 
vitro (Flashman et al., 2010; Knowles et al., 2003). Likewise, EGLN activity in cells can be 
modulated by reactive oxygen species and by intracellular cysteine, which protects the 
EGLNs from oxidative damage (see also below).
Overall, the EGLN-HIF system is remarkably well-conserved throughout evolution, being 
recognizable in the simplest known animal, the placozoan Trichoplax adhaerens (Loenarz et 
al., 2011). The extraordinary diversification of lifeforms during the past 500 million years 
was necessarily associated with higher variability in oxygen tension within larger and more 
complex animals, as well as during development, and it appears that the ancestral oxygen 
sensing was subjected to evolutionary pressure to evolve into a more sophisticated 
machinery. Thus, the genome of higher organisms such as mammals typically generates 
three canonical HIF prolyl hydroxylases, encoded by EGLN1, 2 and 3 genes (with the 
commonly used aliases PHD2, PHD1 and PHD3, respectively), three HIFα subunits 
(encoded by HIF1A, EPAS1/HIF2A and HIF3A) and two HIFβ partners (encoded by 
ARNT1 and 2). Numerous studies based on isoform-specific genetic inactivation have 
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revealed both overlapping and specific functions, with important implications for 
physiology, disease and drug development (Kaelin and Ratcliffe, 2008; Semenza, 2012). The 
importance of this pathway is underscored by the discovery of EGLN1 and EPAS1 genetic 
polymorphisms in human populations living at extremely high altitudes (Bigham and Lee, 
2014).
While EGLN1 is widely recognized as the central hypoxia/oxygen sensor with respect to 
HIF (Berra et al., 2003; Schofield and Ratcliffe, 2004), all three isoforms exhibit enzymatic 
properties consistent with sensing roles, having Km values for O2 above anticipated cellular 
and tissue oxygen levels (Ehrismann et al., 2007; Hirsila et al., 2003), and EGLN2 and 
EGLN3 contribute to the regulation of HIF in certain settings. For example, acutely 
eliminating Egln1 in the mouse liver leads to a pulsatile induction of the canonical HIF-
target Epo, presumably reflecting compensation by Egln2 and Egln3, while eliminating all 3 
paralogs leads to sustained, high-level, hepatic Epo production (Minamishima and Kaelin, 
2010; Querbes et al., 2012). A fourth prolyl hydroxylase termed P4H-TM (alternatively 
known as PHD4), possessing an endoplasmic reticulum transmembrane domain, was 
characterized by Myllyharju, Koivunen and colleagues and shown to control HIF stability 
and erythropoietin production in vivo (Koivunen et al., 2007; Laitala et al., 2012). Overall, 
however, significantly less is known about this enzyme compared to the “original” members 
of the family.
It perhaps makes sense, from an evolutionary standpoint, that oxygen monitoring in more 
complex organisms such as mammals utilizes multiple distinct EGLNs that have different 
oxygen affinities and that are capable of performing specific, in addition to common, 
biochemical functions (Table 1). For example, physiologic oxygen tension varies 
dramatically between organs, from as high as 80–100 mmHg in the lung alveoli and arterial 
blood, to 1–2 mmHg in the renal papilla (Leichtweiss et al., 1969), too wide a window for a 
single enzymatic sensor. Multiple differences are discernible between mammalian EGLN 
isoforms. All three EGLNs hydroxylate the highly conserved Pro564 in HIF1α, but only 
EGLN1 and 2 can modify the more recently evolved Pro402 (Berra et al., 2003; Chowdhury 
et al., 2016). Additionally, the isoforms differ in their affinity for specific HIF isoforms, for 
example EGLN3 exhibits preference for HIF2α (Appelhoff et al., 2004). There is also 
growing evidence that each of the three EGLNs has specific non-HIF targets, as discussed 
below. A summary of EGLN isoform characteristics is provided in Table 1.
As noted by Schofield and colleagues (Markolovic et al., 2015), the 2001 discovery that 
hydroxylation can play physiologically-relevant roles in transcriptional regulation has 
generated considerable interest in the larger class of 2-OG dioxygenases, with its 
approximately 60 members. An important question is whether any of these enzymes, in 
addition to EGLNs, also operate as oxygen sensors under physiological conditions. While, 
by definition, diatomic oxygen is necessary for the function of all these enzymes, most 
exhibit extremely high affinity for oxygen, meaning that they theoretically can remain active 
until cells are virtually anoxic (Salminen et al., 2015; Sanchez-Fernandez et al., 2013). For 
specific members however, evidence of sensor function has been reported. As summarized 
by Rocha and colleagues (Shmakova et al., 2014), moderate hypoxia (1–3% O2) leads to a 
global increase in H3K9me2, H3K9me3 and H3K36me3 in cells, suggesting that hypoxia 
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directly (or indirectly) inhibits certain Jumonji C domain-containing (JMJC) histone 
demethylases such as KDM5A, KDM4D and KDM4E. The available information, although 
still limited, indicates that KDM4E, similar to EGLNs, has a relatively low affinity for 
oxygen compared to other dioxygenases (Shmakova et al., 2014) thus strengthening its 
sensor credentials. Interestingly, many JMJC KDMs, like EGLN1 and EGLN3, are induced 
by hypoxia, (and where studied, HIF), potentially to compensate for decreased activity 
(Shmakova et al., 2014).
Another special case is Factor Inhibiting HIF (FIH1/HIF1AN), which is a stable component 
of chromatin-bound HIF. HIFα has two transactivation domains, called the N-terminal and 
C-terminal transactivation domains (NTAD and CTAD). Rather than acting on proline, FIH 
hydroxylates a specific asparagine in HIFα’s CTAD (Asn803) (Hewitson et al., 2002; Lando 
et al., 2002). In contrast to EGLN-mediated hydroxylation, which dramatically enhances a 
protein-protein interaction (HIF-pVHL), Asn803 hydroxylation disrupts the interaction 
between HIF and its p300/CBP coactivators (Markolovic et al., 2015), thereby crippling the 
CTAD. Based on its higher oxygen affinity compared to EGLNs, FIH maintains sufficient 
activity at intermediate levels of hypoxia that are sufficient to stabilize HIF1α, thus adding a 
second oxygen – mediated checkpoint in the pathway. In contrast to EGLNs, FIH is 
relatively promiscuous, as it can hydroxylate a broad spectrum of additional substrates, 
including Notch (Coleman et al., 2007), cytoskeletal ankyrin family proteins (Yang et al., 
2011a) and the TRPV3 ion channel (Karttunen et al., 2015). Furthermore, in addition to the 
normally preferred asparaginyl, FIH can also hydroxylate histidinyl and aspartyl residues 
(Yang et al., 2011b). Although the roles of FIH in the broader response to hypoxia are still 
being unraveled, its preference of HIF1α over HIF2α has several practical implications. 
First, drugs that block EGLN (see also below), but not FIH, can stimulate EPO without 
inducing VEGF because the former is driven by HIF2 and the latter normally by the HIF1 
CTAD. Second, the presence of FIH does not prevent pVHL-defective kidney cancers from 
coopting the HIF program because these tumors are driven largely by HIF2 rather than HIF1 
(Cho and Kaelin, 2016). From the standpoint of normal physiology, the genetic inactivation 
of Fih in mice does not, surprisingly, generate an obvious phenotype (in stark contrast to 
inactivation of Egln1, Hif1a, or Vhl). Based on its ancient origin and preservation, however, 
one can speculate that FIH confers a fitness advantage by fine-tuning diverse cellular 
pathways.
HIF1 and HIF2: Related, But Far from Identical
Next generation sequencing technology has enabled an increasingly comprehensive 
characterization of the transcription program set in motion by hypoxia and the HIFs. 
Overall, some HIF targets are induced when diverse cell types are subjected to in vitro 
hypoxia, while others, such as the abovementioned EPO, are highly tissue-specific. Upon 
closer examination, the hypoxic response exhibits additional layers of complexity, including 
kinetic differences. Below we will examine the mechanistic basis for the known similarities 
and differences between HIF1 and HIF2, and the resulting implications for disease and 
therapy.
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HIF1 has been traditionally described as the driver of metabolic responses to hypoxia, 
including the control of most glycolytic enzymes, such as phosphofructokinase (PFKFB3), 
lactate dehydrogenase A (LDHA) and pyruvate kinase (PKM). Its metabolic role has been 
expanded to maintenance of intracellular pH, via targets such as monocarboxylate 
transporter 4 (MCT4) and carbonic anhydrase 9 (CA-IX). Furthermore, HIF1 induction 
triggers a multi-pronged suppression of mitochondrial respiration that includes 
transcriptional induction of pyruvate dehydrogenase kinases (PDK1 and PDK3 isoforms) 
(Keith et al., 2011; Kim et al., 2006). Furthermore, as shown by Semenza’s group, HIF1 
reciprocally regulates mitochondrial COX4 subunit expression by activating transcription of 
the gene encoding COX4-2, but also by inducing the gene encoding LONP1, a 
mitochondrial protease that degrades COX4-1. This switch from COX4-1 to COX4-2 
decreases the activity of cytochrome oxidase complex and reduces oxygen consumption 
(Fukuda et al., 2007). On the other hand, HIF2 is viewed as predominantly responsible for 
hypoxic induction of genes linked to growth signals, including TGFA and PDGFB, the cell-
cycle, such as CCND1, stem cell biology, such as OCT4, invasion, such as MMP2 and 
MMP13, and erythropoiesis, such as EPO.
Overall, fundamental differences between HIF1 and HIF2 exist and understanding these 
should be key for rational pharmacological targeting of the oxygen sensing pathway. What 
accounts, at the molecular level, for the differences between HIF siblings? It should be noted 
that the consensus sequence for a Hypoxia Response Element (HRE), (G/C/
T)ACGTGC(G/C), is both short, degenerate, and unable to discriminate between HIF1 and 
HIF2. On the other hand, protein-protein interactions at promoters and enhancers with a 
diverse panel of transcription factors, co-regulators and chromatin remodelers appear to 
exhibit important isoform differences. In short, the ability of a given HRE to support 
activation by HIF1, HIF2, both, or neither is likely influenced by chromatin accessibility and 
neighboring transcription factors.
HIF1 and HIF2 differential interactions with two central growth-promoting drivers, MYC 
and mTORC1, provide key explanations for at least some of the functional contrasts between 
the isoforms. In brief, hypoxic induction of HIF1 prevents MYC from associating with its 
partner MAX and with SP1 transcription factor on chromatin, the net result being 
suppression of MYC-dependent transactivation. Additionally, HIF1 induces MAX interactor 
1 (MXI1), which further inhibits the expression of MYC targets (Dang et al., 2008). A 
caveat is necessary however, as the antagonism between HIF1 and MYC is in fact more 
nuanced, depending on their relative abundance. When MYC family members are highly 
overexpressed, such as in neuroblastoma, they collaborate with HIF1 to boost glycolysis, 
and overcome the inhibitory effects of HIF1 highlighted above, thus allowing proliferation 
under decreased O2 availability (Keith et al., 2011). On the other hand, HIF2α facilitates the 
formation of an active MYC complex and activates a hypoxic pro-growth program. Similar 
contrast has been reported with respect to mTORC1 function. HIF1, but not HIF2, induces 
the expression of DNA-damage-inducible transcript 4 (DDIT4/ REDD1), which releases 
TSC2 from the sequestering effects of 14-3-3 proteins, leading to mTORC1 complex 
inhibition (Keith et al., 2011). Therefore, HIF1 and HIF2 can, at least in some contexts, have 
opposing roles on cell proliferation and growth, such as appears to be the case in pVHL-
defective kidney cancers (Cho and Kaelin, 2016).
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Optimization of EGLN-HIF System by Positive and Negative Feedbacks
Oxygen sensing machinery is subject to regulatory feedbacks, both positive and negative, 
that involve a broad spectrum of components, including proteins, metabolites and the more 
recently appreciated noncoding RNAs. Such mechanisms may play critical roles for the 
differences in timing between HIF1 and HIF2 induction during hypoxia. Thus HIF1 is 
generally thought to coordinate the acute response, with its protein level peaking within the 
first 12 hours, followed by gradual decrease. In contrast, HIF2 exhibits a more delayed 
induction followed by a stable plateau pointing to a role in chronic adaptive responses (Koh 
and Powis, 2012).
One important feedback appears to involve EGLN hydroxylases themselves. EGLN1 and 3 
consistently score as HIF transcriptional targets. One could speculate that their gradual loss 
of function in low oxygen is compensated in part by increased abundance.
A more recently appreciated, yet insufficiently understood, set of feedbacks linked to 
oxygen sensing involves noncoding RNAs (Gee et al., 2014). The noncoding transcriptome 
comprises tens of thousands of RNAs performing biological functions without being 
translated into proteins (Cech and Steitz, 2014). Benefitting from technical advances in RNA 
sequencing, studies performed over the past decade have connected a variety of noncoding 
RNAs to hypoxia responses. With the important caveat that independent validation is not yet 
available for most of these candidates, they may add an important tissue-specific dimension 
to the hypoxic response. Indeed, it is generally agreed that noncoding RNAs exhibit higher 
tissue variability than do coding transcripts. Based on their ability to interact with an 
astonishingly diverse spectrum of protein and nucleic acid targets, noncoding RNAs are 
likely to introduce previously unsuspected regulatory feedbacks in the hypoxic response.
Historically, the first family of noncoding RNAs to be linked to hypoxia were microRNAs 
(miRNAs)(Kulshreshtha et al., 2007b). These are short oligoribonucleotides (approximately 
22nt in length) known to repress the expression of target gene by promoting mRNAs 
degradation and/or translation blockade. While low oxygen tension globally downregulates 
miRNAs biogenesis (Rupaimoole et al., 2014; van den Beucken et al., 2014), a select few 
mature miRNAs are induced by hypoxia in multiple cell types. In particular, miR-210 has 
been identified as direct HIF target by multiple groups and is consistently induced by 
hypoxia in normal and transformed cells (Chan et al., 2009; Gee et al., 2014; Kulshreshtha et 
al., 2007a). As summarized in Fig. 1, arguably the most robust targets of miR-210 are ISCU, 
an assembly factor for Fe-S complexes required for ETC activity (Chan and Loscalzo, 2010; 
Favaro et al., 2010), and NDUFA4, which is an integral component of ETC complex IV 
(Balsa et al., 2012; Fasanaro et al., 2009). Elevated miR-210 expression in hypoxia 
downregulates ISCU and NDUFA4, thus reducing electron transfer complex activity. This 
noncoding arm of HIF may reinforce the HIF1-mediated suppression of mitochondrial 
respiration via the coding gene products discussed above. Collectively, these suppressive 
effects on mitochondrial respiration are thought to decrease oxygen consumption and 
thereby help restore cellular oxygenation.
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Multiple studies have provided evidence for miRNA-based feedbacks that affect the 
expression of HIF itself, in hypoxic or non-hypoxic contexts. For example miR-218 was 
shown to be downregulated in mesenchymal glioblastoma and involved in resistance to 
chemotherapy. Mechanistically, low miR-218 releases multiple RTK effectors from its 
inhibitory control, leading to activation of hypoxia-inducible factors, most notably HIF2α 
(Mathew et al., 2015). As shown by Cormac Taylor’s group, induction of miR-155 by 
hypoxia appears to be part of a complex feedback mechanism that generates an oscillatory 
pattern for HIF1 transcriptional activity (Bruning et al., 2011). Given the generally 
acknowledged subtle effects of miRNAs, especially when expressed at physiological levels, 
and taking into account their probable distribution between many targets, a measurable 
impact on HIF abundance may require cooperative action. As shown by Maria Czyzyk-
Krzeszka’s group in the context of VHL-deficient clear cell renal carcinoma (Mikhaylova et 
al., 2012), responses involving coding and noncoding transcripts can cooperate. In particular, 
VHL induces miR-204, which downregulates MAP1LC3B (LC3B) and as consequence 
decreases macro-autophagic activity. In parallel, VHL, by suppressing HIF, also 
transcriptionally suppresses LC3C. This dual mechanism of autophagy blockade appears to 
contribute to VHL tumor-suppressor function (Mikhaylova et al., 2012). More recently, 
Celeste Simon and colleagues generated evidence of a HIF-independent mechanism that 
shifts the balance between the pro- and anti-tumorigenic effects of HIFα isoforms (Mathew 
et al., 2014). In a subset of clear cell renal cell carcinomas that expresses both isoforms, they 
have identified consistent downregulation miR-30c-2-3p and miR-30a-3p. As these miRNAs 
target HIF2α, but not HIF1α, a decrease in their expression selectively increases the 
abundance of the former, pro-oncogenic, HIFα isoform.
The more recently studied long-noncoding RNAs (lncRNAs) form a vast and heterogeneous 
family of transcripts larger than 200nt in length. Chronologically, one of the first genomic 
loci reported to generate a hypoxia-inducible lncRNAs was HIF1A gene itself (Thrash-
Bingham and Tartof, 1999). The negative strand of this locus produces multiple antisense 
noncoding transcripts in response to hypoxia, the highest expressed being HIF1-AS2 (Mineo 
et al., 2016). This is in contrast to HIF1A mRNA, which is typically downregulated or 
unchanged in hypoxia. The antisense HIF transcript is important for the hypoxic process 
itself, as its knockdown blunts the induction of HIF2α and that of important HIF targets 
(NDRG1, VEGFA and ADM). While a direct connection to HIF itself remains elusive, the 
above study identified several RNA-binding proteins interacting with HIF1A-AS2, including 
IGF2BP2 and DHX9, which may explain its importance for the hypoxic response. 
Consistently, loss of HIF1A-AS2 suppresses tumor cell viability and delays xenograft 
growth (Mineo et al, 2016). The various feedbacks involving noncoding RNAs described 
above are summarized in Fig 2.
EGLN-HIF Beyond Conventional Hypoxic Responses
It has become evident that EGLN enzymes respond to other inputs in addition to hypoxia. 
For example, mutations in fumarate hydratase (FH) and succinate dehydrogenase subunits 
(SDHA, SDHC, SDHD) identified in rare kidney cancers and neuroendocrine tumors disrupt 
the normal TCA cycle metabolite flow and cause the accumulation of fumarate and 
succinate, respectively, which then inhibit the EGLNs by competing with their natural co-
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substrate, 2-oxoglutarate. It was recently shown that acidosis and hypoxia, commonly 
coexisting in the tumor microenvironment, favor the accumulation of L-2-hydroxyglutarate 
(Intlekofer et al., 2017; Nadtochiy et al., 2016), an endogenous 2-oxoglutarate antagonist 
(Xu et al., 2011). Theoretically, this process could reinforce EGLN1inhibition in solid 
tumors. A recent study provides evidence that EGLN1 has an even wider metabolite-sensing 
capacity. Triple negative breast cancer cells secrete glutamate, which inhibits the xCT 
glutamate-cystine antiporter, leading to intracellular cysteine depletion. EGLN1 appears to 
be particularly sensitive to absence of cysteine, and undergoes oxidative self-inactivation, 
ultimately resulting in HIF1α accumulation (Briggs et al., 2016)..
EGLN substrates other than the HIFs are beginning to emerge and might provide previously 
unsuspected connections between oxygen sensing, nutrient sensing, and growth responses. 
For example, AKT1 and AKT2 kinases, which control growth and metabolism, are 
negatively regulated by EGLN1-mediated hydroxylation under normoxia (Guo et al., 2016). 
A case reminiscent of the EGLN-HIF-VHL relationship is provided by NDRG family 
member 3 (NDRG3). Under normoxic conditions, NDRG3 is marked for VHL-dependent 
ubiquitination by EGLN1-mediated prolyl hydroxylation. Interestingly, its hypoxic 
stabilization, which contributes to Raf-ERK pathway activation, also requires direct binding 
of lactate, thus establishing a novel connection between oxygen sensing, metabolic 
reprogramming and oncogenic signaling (Lee et al., 2015). Another example of EGLN 
function outside of the HIF network is provided by EGLN2. Hydoxylation of FOXO3a by 
EGLN2 destabilized FOXO3a by preventing its interaction with the USP9x deubiquitinase 
(Zheng et al., 2014). EGLN3-mediated hydroxylation of Acetyl-CoA Carboxylase (ACC2) 
leads to decreased fatty acid oxidation under normoxia and high nutrient availability 
(German et al., 2016). Pyruvate kinase M2, the proliferogenic splice form of pyruvate 
kinase, appears to be another major metabolic enzyme serving as hydroxylation substrate. 
Hydroxylation of prolines 403/408 by EGLN3 stimulates PKM2 catalytic activity and also 
allows PKM2, through direct binding, to promote HIF transcriptional activity (Luo et al., 
2011). Furthermore, Stamler and colleagues (Xie et al., 2009) showed that EGLN3 can also 
hydroxylate the β2 adrenergic receptor at two proline residues (Pro-382 and -395) in 
normoxic conditions. This event triggers the recruitment of the pVHL ubiquitin ligase 
complex and subsequent proteasomal degradation of the receptor. These results unveil a 
surprisingly broad reach of hydroxylation-based signaling and may suggest new avenues for 
translational applications. An important caveat is that all the hydroxylation targets 
summarized above, with the exception of HIFα, await independent validation.
Pharmacological Inhibition of HIF
The knowledge that solid tumors contain hypoxic regions fueled considerable interest in the 
development of HIF inhibitors, with virtually all early efforts focused on HIF1. Progress was 
impeded, however, by the prevailing dogma that bHLH-PAS domain proteins were 
“undruggable”. Bruick and Gardner, however, identified a druggable hydrophobic pocket in 
the HIF2α PAS B domain, which led to the development of the first generation of small 
molecule HIF2 inhibitors (Scheuermann et al., 2009). Two of these compounds, the lead 
compound PT2385 and the related tool compound PT2399, selectively disrupt HIF2α’s 
interaction with ARNT and suppress pVHL-defective kidney cancers in preclinical models 
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(Cho and Kaelin, 2016). Based on the promising preclinical data, PT2385 has entered 
clinical trials with early signs of activity. Nonetheless, de novo and acquired resistance to 
PT2385/2399 has already been documented in the laboratory (Cho and Kaelin, 2016). 
Current work is aimed at circumventing this resistance as well as identifying other tumor 
types where HIF2 plays a role in tumor maintenance. A cautionary tale in this regard is 
provided by the analysis of tumors, such as KRAS-driven lung cancers in genetically-
engineered mice, where disruption of HIF2 actually accelerates tumor growth (Mazumdar et 
al., 2010). This again underscores the importance of context with respect to the HIF 
response.
Likewise, HIF1 may still hold significant value as target in solid tumors. In general, HIF1 
contributes to the Warburg Effect, which is believed to provide building blocks for 
anabolism, and promotes survival under hypoxic conditions through cell-intrinsic changes 
in, for example, ATP synthesis and turnover, and cell-extrinsic changes, such as induction of 
angiogenesis. As discussed above, mTORC1 blockade by HIF1 may benefit tumor cells 
residing in the perinecrotic areas where very low or absent oxygen is accompanied by 
nutrient deprivation and acidity. Cell survival under such conditions includes strategies such 
as suppression of ATP-intensive processes (e.g. protein translation, lipid synthesis), 
activation of mitophagy, and exit from the cell-cycle, all processes mediated by HIF1 rather 
than HIF2. Indeed, the HIF2-driven growth program would be incompatible with cell 
survival under these circumstances. HIF1 targeting may also be valuable as part of combined 
interventions, for example with radiation or antiangiogenic agents (McIntyre and Harris, 
2015). The recent discovery that the HIF1 PAS domains, like the HIF2 PAS domain, contain 
hydrophobic pockets should stimulate efforts to identify direct HIF1 antagonists (Wu et al 
Nature 2015). In addition, acriflavine and proflavine were identified in a phenotypic screen 
for HIF1 inhibitors and appear to target a HIF1α/ARNT interface (Wilkins et al., 2016). 
Many other compounds have been identified that can, at least indirectly, downregulate HIF1 
(Xia et al., 2012). A caveat with these indirect inhibitors is that HIF1 turns over very rapidly 
and therefore will be one of the first proteins to disappear when cells are confronted with a 
toxic agent that can decrease global transcription or translation.
Pharmacological Activation of the Hypoxic Response
Many diseases of the developed world are linked to inadequate oxygen delivery, including 
anemia, myocardial infarction, and stroke. The realization that HIFs are negatively regulated 
by enzymes opened the way for the development of a new class of pharmacological agents 
capable of stabilizing HIF and activating the hypoxic response. The first generation of 
EGLN inhibitors have advanced to phase II/III clinical trials for patients with anemia linked 
to chronic renal failure and appears promising, based on preclinical data, for treating other 
types of anemia, such as anemia of chronic disease, as well as diseases linked to regional 
ischemia (Maxwell and Eckardt, 2016).
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Figure 1. 
Model of cooperation between coding genes and miR-210 downstream of HIF1. Feedback 
loop leading to renormalization of local O2 tension as a result of decreased local 
consumption.
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Figure 2. 
Model of noncoding RNA-based feedback circuits optimizing the transition from a HIF1 to 
a HIF2-based hypoxic response.
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Table 1
Summary of EGLN isoform distinguishing features
Enzyme
name
Preferred HIF
isoform
Specific features
EGLN1 (PHD2) HIF1α (both NTAD and CTAD) Lowest O2 affinity (main sensor); Knockout embryonically lethal
EGLN2 (PHD1) HIF2α (both NTAD and CTAD) Estrogen-inducible; Transcript not induced by hypoxia; Potential oncogene
EGLN3 (PHD3) HIF2α (only CTAD) Regulator of apoptosis; Multiple non-HIF target candidates
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